Shots: Dicerna to receive $175M up front, $50M equity investment, $75M for first three years of collaboration and up to $375.5M/ target as development, regulatory and commercialization milestones with royalties […]readmore
Tags : RNAi Therapies
Shots: OliX to receive $2.27M upfront, clinical milestones and royalties on sales of product. Thea to get license rights to develop & commercialize OLX301A in EU, Middle East and Africa […]readmore